MCID: BNC003
MIFTS: 58

Bone Cancer

Categories: Bone diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Bone Cancer

MalaCards integrated aliases for Bone Cancer:

Name: Bone Cancer 12 42 15
Malignant Bone Neoplasm 12 17 71
Bone Carcinoma 12 15 71
Bone Neoplasms 74 44 71
Bone Neoplasm 12 17
Malignant Neoplasm of Bone 12
Malignant Osseous Tumor 12
Malignant Bone Tumour 12
Osteosarcoma of Bone 71
Osteogenic Neoplasm 71
Ca - Bone Cancer 12
Neoplasm of Bone 12
Osseous Tumor 12
Bone Tumour 12

Classifications:



External Ids:

Disease Ontology 12 DOID:184 DOID:2762
MeSH 44 D001859
NCIt 50 C36082 C9343
SNOMED-CT 67 126537000 269568000
UMLS 71 C0005967 C0279530 C0585442 more

Summaries for Bone Cancer

MedlinePlus : 42 Cancer that starts in a bone is uncommon. Cancer that has spread to the bone from another part of the body is more common. There are three types of bone cancer: Osteosarcoma - occurs most often between ages 10 and 19. It is more common in the knee and upper arm. Chondrosarcoma - starts in cartilage, usually after age 40 Ewing's sarcoma - occurs most often in children and teens under 19. It is more common in boys than girls. The most common symptom of bone cancer is pain. Other symptoms vary, depending on the location and size of the cancer. Surgery is often the main treatment for bone cancer. Other treatments may include amputation, chemotherapy, and radiation therapy. Because bone cancer can come back after treatment, regular follow-up visits are important. NIH: National Cancer Institute

MalaCards based summary : Bone Cancer, also known as malignant bone neoplasm, is related to primary bone cancer and osteogenic sarcoma, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Bone Cancer is TNFSF11 (TNF Superfamily Member 11), and among its related pathways/superpathways are GPCR Pathway and ERK Signaling. The drugs Pregabalin and Immunoglobulin G have been mentioned in the context of this disorder. Affiliated tissues include bone, prostate and spinal cord, and related phenotypes are growth/size/body region and behavior/neurological

Disease Ontology : 12 A connective tissue cancer that is located in bone and is characterized by uncontrolled cellular proliferation that destroys normal bone tissue.

Wikipedia : 74 A bone tumor is a neoplastic growth of tissue in bone. Abnormal growths found in the bone can be either... more...

Related Diseases for Bone Cancer

Diseases in the Bone Cancer family:

Primary Bone Cancer

Diseases related to Bone Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 407)
# Related Disease Score Top Affiliating Genes
1 primary bone cancer 32.7 MRC2 MAPK7
2 osteogenic sarcoma 32.6 TP53 TNFSF11 MMP9 IL6 CYCS CDKN2A
3 bone squamous cell carcinoma 32.3 TP53 MMP9 EGFR CDKN2A
4 li-fraumeni syndrome 32.1 TP53 ESR1 EGFR CDKN2A
5 bone disease 31.2 TNFSF11 MMP9 IL6 ESR1 COL1A1 CCL2
6 bone resorption disease 31.2 TNFSF11 IL6 ESR1 COL1A1 BMP2
7 ewing sarcoma 31.1 TP53 MMP9 EGFR CDKN2A BMI1
8 pain agnosia 31.1 TRPV1 PENK PDYN IL6
9 keratocystic odontogenic tumor 30.9 TP53 TNFSF11 MMP9
10 chordoma 30.8 TP53 MTAP EGFR CDKN2A
11 osteomyelitis 30.7 TNFSF11 IL6 CCL2 BMP2
12 myeloma, multiple 30.6 TP53 TNFSF11 IL6 EGFR CYCS CDKN2A
13 neurofibroma 30.6 TP53 EGFR CDKN2A
14 fasciitis 30.5 TP53 IL6 ESR1
15 bone inflammation disease 30.5 TNFSF11 MMP9 IL6 CCL2
16 pigmented villonodular synovitis 30.5 TP53 TNFSF11 MMP9
17 osteonecrosis 30.4 TNFSF11 ESR1 BMP2
18 prostate cancer 30.4 TP53 TNFSF11 MMP9 MAPK7 IL6 ESR1
19 mammary paget's disease 30.4 TNFSF11 ESR1 EGFR
20 meningioma, familial 30.3 TP53 PENK ESR1 EGFR CDKN2A
21 burkitt lymphoma 30.3 TP53 IL6 CYCS CDKN2A BMI1
22 oral cancer 30.3 TP53 MMP9 EGFR CDKN2A
23 breast adenocarcinoma 30.3 TP53 TNFSF11 MMP9 ESR1 EGFR CYCS
24 pheochromocytoma 30.3 PENK PDYN IL6 ESR1 CYCS CDKN2A
25 ameloblastoma 30.3 TP53 TNFSF11 MMP9
26 dermatofibrosarcoma protuberans 30.3 TP53 COL1A1 CDKN2A
27 estrogen-receptor positive breast cancer 30.3 TP53 ESR1 EGFR
28 adenoid cystic carcinoma 30.2 TP53 MMP9 EGFR CDKN2A
29 mantle cell lymphoma 30.2 TP53 IL6 CDKN2A BMI1
30 peripheral nervous system disease 30.2 TRPV1 TP53 MMP9 IL6 EGFR CYCS
31 skin carcinoma 30.2 TP53 MMP9 IL6 ESR1 EGFR CDKN2A
32 osteoporosis 30.2 TRPV1 TP53 TNFSF11 P2RX7 MMP9 IL6
33 carcinosarcoma 30.2 TP53 EGFR CDKN2A
34 esophageal cancer 30.2 TP53 MMP9 IL6 EGFR CYCS CDKN2A
35 bone marrow cancer 11.4
36 chest wall bone cancer 11.2
37 maxillary cancer 11.0
38 mesenchymal chondrosarcoma 11.0
39 clear cell chondrosarcoma 11.0
40 aneurysmal bone cysts 10.9
41 bone sarcoma 10.9
42 enchondromatosis, multiple, ollier type 10.9
43 retinoblastoma 10.9
44 paget's disease of bone 10.9
45 rapadilino syndrome 10.8
46 rothmund-thomson syndrome, type 2 10.8
47 long bones of lower limb cancer 10.8
48 diamond-blackfan anemia 10.8
49 jaw cancer 10.8
50 orbital cancer 10.8

Graphical network of the top 20 diseases related to Bone Cancer:



Diseases related to Bone Cancer

Symptoms & Phenotypes for Bone Cancer

UMLS symptoms related to Bone Cancer:


back pain, sciatica, muscle cramp

MGI Mouse Phenotypes related to Bone Cancer:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.47 ATF3 BMP2 CDKN2A COL1A1 CYCS EGFR
2 behavior/neurological MP:0005386 10.46 ATF3 CDKN2A COL1A1 CYCS ESR1 IL6
3 immune system MP:0005387 10.44 ATF3 BMP2 CCL2 CDKN2A COL1A1 CYCS
4 cardiovascular system MP:0005385 10.42 BMP2 CDKN2A COL1A1 CYCS EGFR ESR1
5 homeostasis/metabolism MP:0005376 10.42 ATF3 BMP2 CDKN2A COL1A1 EGFR ESR1
6 cellular MP:0005384 10.41 BMP2 CDKN2A COL1A1 CYCS EGFR ESR1
7 hematopoietic system MP:0005397 10.4 ATF3 BMP2 CDKN2A COL1A1 CYCS EGFR
8 integument MP:0010771 10.37 ATF3 CDKN2A COL1A1 EGFR ESR1 IL6
9 digestive/alimentary MP:0005381 10.29 BMP2 CDKN2A COL1A1 EGFR ESR1 IL6
10 adipose tissue MP:0005375 10.27 ATF3 COL1A1 EGFR ESR1 IL6 PDYN
11 endocrine/exocrine gland MP:0005379 10.27 ATF3 CDKN2A COL1A1 CYCS EGFR ESR1
12 nervous system MP:0003631 10.25 ATF3 BMP2 CDKN2A COL1A1 CYCS EGFR
13 embryo MP:0005380 10.24 BMP2 CDKN2A COL1A1 CYCS EGFR ESR1
14 neoplasm MP:0002006 10.16 ATF3 CDKN2A COL1A1 EGFR ESR1 IL6
15 muscle MP:0005369 10.13 CDKN2A COL1A1 EGFR ESR1 IL6 MAPK7
16 limbs/digits/tail MP:0005371 10.11 BMP2 COL1A1 EGFR ESR1 MMP9 P2RX7
17 liver/biliary system MP:0005370 10.1 CDKN2A COL1A1 EGFR ESR1 IL6 MTAP
18 no phenotypic analysis MP:0003012 10.1 ATF3 CDKN2A COL1A1 EGFR ESR1 PDYN
19 normal MP:0002873 10.02 BMP2 COL1A1 EGFR ESR1 MAPK7 MRC2
20 reproductive system MP:0005389 9.96 BMP2 CDKN2A COL1A1 EGFR ESR1 IL6
21 renal/urinary system MP:0005367 9.92 COL1A1 EGFR ESR1 IL6 MAPK7 MMP9
22 respiratory system MP:0005388 9.85 ATF3 CDKN2A COL1A1 EGFR ESR1 IL6
23 skeleton MP:0005390 9.77 BMP2 CDKN2A COL1A1 CYCS EGFR ESR1
24 vision/eye MP:0005391 9.32 ATF3 CDKN2A COL1A1 EGFR IL6 MMP9

Drugs & Therapeutics for Bone Cancer

Drugs for Bone Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
2 Immunoglobulin G Phase 4
3 Immunoglobulins, Intravenous Phase 4
4 Analgesics Phase 4
5 Hormones Phase 4
6 Anticonvulsants Phase 4
7 Psychotropic Drugs Phase 4
8 Calcium, Dietary Phase 4
9 Anti-Anxiety Agents Phase 4
10 calcium channel blockers Phase 4
11
Calcium Nutraceutical Phase 4 7440-70-2 271
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
13
Zoledronic Acid Approved Phase 2, Phase 3 118072-93-8 68740
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
16
Phenol Approved, Experimental Phase 3 108-95-2 996
17
Ethanol Approved Phase 3 64-17-5 702
18
Captopril Approved Phase 3 62571-86-2 44093
19 Grape Approved Phase 3
20 Cranberry Approved, Investigational Phase 3
21
Cefazolin Approved Phase 3 25953-19-9 656510 33255
22
Daunorubicin Approved Phase 3 20830-81-3 30323
23
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
24
Tranexamic Acid Approved Phase 3 1197-18-8 5526
25
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
26
Molybdenum Approved Phase 3 7439-98-7 185498
27
Camptothecin Experimental Phase 3 7689-03-4
28 Immunoglobulins Phase 3
29 Antibodies Phase 3
30 Antibodies, Monoclonal Phase 3
31 Narcotics Phase 3
32 Anesthetics, Intravenous Phase 3
33 Anesthetics, General Phase 3
34 Hormone Antagonists Phase 3
35 Antineoplastic Agents, Hormonal Phase 3
36 Antiemetics Phase 3
37 glucocorticoids Phase 3
38 Mitogens Phase 2, Phase 3
39 Endothelial Growth Factors Phase 2, Phase 3
40 BB 1101 Phase 3
41 Antihypertensive Agents Phase 3
42 Diphosphonates Phase 3
43 Polymethyl Methacrylate Phase 3
44 Angiotensin-Converting Enzyme Inhibitors Phase 3
45
protease inhibitors Phase 3
46 HIV Protease Inhibitors Phase 3
47 Vaccines Phase 3
48 Anti-Infective Agents Phase 3
49 Antitubercular Agents Phase 3
50 Cephalosporins Phase 3

Interventional clinical trials:

(show top 50) (show all 214)
# Name Status NCT ID Phase Drugs
1 Open-Label Study to Establish the Short Term Efficacy of Intravenous Loading-Doses of Bondronat 6 mg in Patients With Breast Cancer and Skeletal Metastases Experiencing Moderate to Severe Pain, Within 7 Days After Initiation of Treatment Completed NCT02553707 Phase 4 Ibandronate
2 An Open Label Study of the Efficacy, Safety, and Pharmacoeconomics of Oral Ibandronate (Bondronat 50 mg) in Treatment of Metastatic Bone Disease Completed NCT02564107 Phase 4 Ibandronate
3 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
4 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
5 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
6 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
7 A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid and Circulating Tumor Cell Measurements in Patients With HER2-negative Metastatic Breast Cancer Without Bone Metastasis Completed NCT01129336 Phase 4 Zoledronic acid;Standard Therapy
8 A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis Completed NCT00334139 Phase 4 Zoledronic Acid
9 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
10 Bioactive Glass Granules as Bone Graft Substitute in Filling Material of Bone Defects Completed NCT01304121 Phase 4
11 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
12 A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride Recruiting NCT02312960 Phase 4
13 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Active, not recruiting NCT03301857 Phase 4 Denosumab (Cohort A)
14 An Open-label, Multi-center, Phase 4 Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone Not yet recruiting NCT04586660 Phase 4 XGEVA®
15 Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer: A Non-inferiority, Randomized, Open, Parallel and Controlled Prospective Clinical Study Not yet recruiting NCT02480634 Phase 4 Zoledronic acid
16 A Randomized Placebo-Controlled Trial Of The Efficacy And Tolerability Of Flexibly Dosed Pregabalin In The Treatment Of Cancer-Induced Bone Pain Terminated NCT00381095 Phase 4 Pregabalin;Placebo
17 Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases: a Randomized Phase II/III Trial Unknown status NCT01429493 Phase 2, Phase 3
18 Laser Therapy Prevents Mucositis Oral in Patients Undergoing to Chemotherapy for Bone Marrow Transplantation? A Randomized Clinical Trial. Unknown status NCT02020928 Phase 3
19 Phase 3 Study Evaluating Fentanyl Transmucosal in the Prevention of Pain Induced by Mobilization During Radiotherapy in Patients With Bone Metastasis Unknown status NCT02426697 Phase 3 fentanyl transmucosal;Placebo
20 18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques Unknown status NCT00882609 Phase 3
21 Clinical, Pathologic Characteristics and Its Mechansim of Denosumab Treated Giant Cell Tumor of Bone Unknown status NCT03259152 Phase 3 Denosumab
22 Randomized, Open Label Study to Evaluate Renal Safety of Intravenous Bondronat 6 mg Infusions Over 15 Minutes Versus 60 Minutes in Patients With Metastatic Bone Disease Due to Breast Cancer Completed NCT02716792 Phase 3 Ibandronate
23 Randomized, Open Label Study to Assess the Efficacy and Safety of the Intravenous and Oral Ibandronic Acid for Improving the Performance Status of Patients With Malignant Bone Disease Secondary to Solid Tumors and Hematological Malignancies Completed NCT02561039 Phase 3 Ibandronate
24 A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms Completed NCT02163226 Phase 2, Phase 3
25 Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer Completed NCT01419717 Phase 3 Denosumab
26 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. Completed NCT00330759 Phase 3 Zoledronic Acid
27 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer Completed NCT00321464 Phase 3 Zoledronic Acid
28 A Randomized, Double-blind, Multi-centre Study to Evaluate the Fficacy and Safety of Zometa as a Treatment in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma Completed NCT00219258 Phase 3 Zoledronic acid
29 Investigation of Optimal Radiotherapy Regimen and Type of Irradiation in Treatment of Painful Bone Metastasis Completed NCT00610272 Phase 3
30 A Randomized Phase III Double-Blind Study of Dexamethasone Versus Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases Completed NCT01248585 Phase 3 Dexamethasone;Placebo
31 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer Completed NCT00321620 Phase 3 zoledronic acid
32 Phase III Study of Palliative Radiotherapy for Bone Metastases Comparing Single to Multiple Fractions. Completed NCT00858741 Phase 3
33 An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma Completed NCT00950911 Phase 3 amg 162
34 Randomized Phase 2 Study on the Relationship Between Circulating VEGF and Weekly or Every-four-week Zometa in Breast Cancer Patients With Bone Metastases Completed NCT00524849 Phase 2, Phase 3 Zoledronic acid
35 Dexamethasone for the Prevention of a Pain Flare After Palliative Radiotherapy for Painful Bone Metastases: a Multi-center Double-blind Placebo-controlled Randomized Study Completed NCT01669499 Phase 3 Dexamethasone acetate;Placebo
36 Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients With Bone Metastases Recruiting NCT04307914 Phase 3
37 A Multi-center, Randomized, Double-blind, Comparative Study to Evaluate the Clinical Efficacy and Safety of QL1206 and Xgeva® in Patients With Bone Metastases From Solid Tumors Recruiting NCT04550949 Phase 3 QL1206;Xgeva
38 Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone: A Prospective Randomized Controlled Trial Recruiting NCT03295981 Phase 3 Zoledronic Acid
39 Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia Recruiting NCT03389724 Phase 3 Capoten®
40 Tranexamic Acid (TXA) to Reduce Volume Of Blood Transfused In Pediatric And Young Adult Cancer Patients Undergoing Limb Salvage Procedure Of A Lower Extremity Recruiting NCT04410042 Phase 3 Tranexamic Acid
41 A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma Active, not recruiting NCT03495921 Phase 3 Irinotecan;Temozolomide
42 Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Multi-Center International Randomized Controlled Trial Comparing Alternative Antibiotic Regimens in Patients Undergoing Tumor Resections With Endoprosthetic Replacements Active, not recruiting NCT01479283 Phase 3 24-Hour Prophylactic Cefazolin* Antibiotic Regimen;5-Days Prophylactic Cefazolin* Antibiotic Regimen
43 Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Active, not recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Ifosfamide;Vincristine;Vincristine Sulfate
44 Postoperative Bleeding Prevention in Massive Bone Tumour Resection: a Multicentric, Randomized, Parallel, Controlled Trial to Assess the Efficacy of Tranexamic Acid Versus Evicel® and Usual Haemostasis Terminated NCT02153593 Phase 3 Tranexamic Acid;Fibrin glue
45 A Randomized, Placebo-controlled, Double-blind Study of the Effect of Bondronat Compared With Zoledronic Acid on Pain in Patients With Malignant Bone Disease Experiencing Moderate to Severe Pain Terminated NCT00099203 Phase 3 ibandronate [Bondronat];zoledronic acid
46 A Prospective, Randomized Pilot Study of Enbrel VS Placebo in Patients Receiving Radiation Therapy to Combat Fatigue and Cachexia Terminated NCT00127387 Phase 2, Phase 3 Enbrel
47 A Randomized, Double-blind Study of the Effect of Bondronat Compared With Zoledronic Acid on Pain in Patients With Malignant Bone Disease Experiencing Moderate to Severe Pain Terminated NCT00099177 Phase 3 ibandronate [Bondronat];zoledronic acid
48 A Cross-over Comparison of the Diagnostic Accuracy of Technetium (99mTc) Medronate Injection Prepared With 99mTc Derived From Neutron-activation Produced 99Mo Versus the Current Reference Standard of 99mTc Derived From Fission-produced 99Mo Terminated NCT03002454 Phase 3 99mTc MDP Injection:neutron-bombardment
49 Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions Withdrawn NCT00851162 Phase 2, Phase 3
50 Primary Pain Palliation and Local Tumor Control in Bone Metastases Treated With Magnetic Resonance-guided Focused Ultrasound Unknown status NCT01693770 Phase 1, Phase 2

Search NIH Clinical Center for Bone Cancer

Inferred drug relations via UMLS 71 / NDF-RT 51 :


ZOLEDRONIC
zoledronic acid

Cochrane evidence based reviews: bone neoplasms

Genetic Tests for Bone Cancer

Anatomical Context for Bone Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Bone Cancer:

19
Bone

MalaCards organs/tissues related to Bone Cancer:

40
Bone, Prostate, Spinal Cord, Breast, Dorsal Root Ganglion, Brain, Bone Marrow

Publications for Bone Cancer

Articles related to Bone Cancer:

(show top 50) (show all 1689)
# Title Authors PMID Year
1
Ablation, Osteoplasty, Reinforcement, and Internal Fixation for Percutaneous Endoskeletal Reconstruction of Periacetabular and Other Periarticular Osteolytic Metastases. 42
33438931 2021
2
Clinicopathologic features of single bone metastasis in breast cancer. 42
33429799 2021
3
Diagnosis and referral of adults with suspected bony metastases. 42
33495231 2021
4
Magnetic bioactive glasses/Cisplatin loaded-chitosan (CS)-grafted- poly (ε-caprolactone) nanofibers against bone cancer treatment. 61
33593554 2021
5
miR-485-3p regulated by MALAT1 inhibits osteosarcoma glycolysis and metastasis by directly suppressing c-MET and AKT3/mTOR signalling. 61
33358903 2021
6
Transformed notochordal cells trigger chronic wounds destabilizing the vertebral column and bone homeostasis. 61
33579726 2021
7
Design strategies and evolving role of biomaterial assisted treatment of osteosarcoma. 61
33579498 2021
8
GEM-Based Metabolic Profiling for Human Bone Osteosarcoma under Different Glucose and Glutamine Availability. 61
33540580 2021
9
Identifying biomolecules and constructing a prognostic risk prediction model for recurrence in osteosarcoma. 61
33376666 2021
10
Hierarchically Porous Osteoinductive Poly(hydroxyethyl methacrylate-co-methyl methacrylate) Scaffold with Sustained Doxorubicin Delivery for Consolidated Osteosarcoma Treatment and Bone Defect Repair. 61
33395260 2021
11
Horseradish Peroxidase-Crosslinked Calcium-Containing Silk Fibroin Hydrogels as Artificial Matrices for Bone Cancer Research. 61
33522095 2021
12
Ubiquitin-specific protease 6 functions as a tumor suppressor in Ewing Sarcoma through immune activation. 61
33558334 2021
13
Blockade of spinal dopamine D1/D2 receptor suppresses activation of NMDA receptor through Gαq and Src kinase to attenuate chronic bone cancer pain. 61
33364051 2021
14
Blockade of Spinal EphA4 Reduces Chronic Inflammatory Pain in Mice. 61
33541257 2021
15
Sol-gel-derived 58S bioactive glass containing holmium aiming brachytherapy applications: A dissolution, bioactivity, and cytotoxicity study. 61
33321639 2021
16
18F-labeled bisphosphonate as an alternative candidate to the gold standard [18F]sodium fluoride ([18F]NaF) for PET bone imaging. 61
33593263 2021
17
The role of the M1/M2 microglia in the process from cancer pain to morphine tolerance. 61
33220596 2021
18
An Analysis of Vertebral Body Growth after Proton Beam Therapy for Pediatric Cancer. 61
33477867 2021
19
The circular RNA circSlc7a11 promotes bone cancer pain pathogenesis in rats by modulating LLC-WRC 256 cell proliferation and apoptosis. 61
33433832 2021
20
Physiologic osteoclasts are not sufficient to induce skeletal pain in mice. 61
32955748 2021
21
Augmented Antitumor Activity for Novel Dual PI3K/BDR4 Inhibitors, SF2523 and SF1126 in Ewing Sarcoma. 61
33480647 2021
22
Bone Marrow Adipocytes: A Link between Obesity and Bone Cancer. 61
33498240 2021
23
Systems Biology Analysis for Ewing Sarcoma. 61
33326111 2021
24
YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells. 61
33419969 2021
25
Systems for local, sustained release of zoledronic acid as a potential treatment for metastatic bone disease. 61
33255000 2021
26
Surgical Advances in Osteosarcoma. 61
33494243 2021
27
Bupivacaine and Lidocaine Induce Apoptosis in Osteosarcoma Tumor Cells. 61
33009230 2021
28
Effect of activation of the Akt/mTOR signaling pathway by EEF1A2 on the biological behavior of osteosarcoma. 61
33569460 2021
29
Circular RNA hsa_circ_0000658 inhibits osteosarcoma cell proliferation and migration via the miR-1227/IRF2 axis. 61
33264494 2021
30
Unusual presentation of lumbar chordoma on bone scintigraphy in a young patient. 61
33392355 2021
31
Circ_0056285 Regulates Proliferation, Apoptosis and Glycolysis of Osteosarcoma Cells via miR-1244/TRIM44 Axis. 61
33603471 2021
32
Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma. 61
33503424 2021
33
Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. 61
33408328 2021
34
Risk of cancer in patients with ankylosing spondylitis: a nationwide cohort study in Taiwan. 61
33464145 2021
35
Pain Biomarkers in Cancer: An Overview. 61
33138755 2021
36
New sol-gel-derived magnetic bioactive glass-ceramics containing superparamagnetic hematite nanocrystals for hyperthermia application. 61
33545853 2021
37
Modeling of osteosarcoma with induced pluripotent stem cells. 61
33022533 2020
38
The Association between Community Water Fluoridation and Bone Diseases: A Natural Experiment in Cheongju, Korea. 61
33316869 2020
39
Autophagy in Osteosarcoma Cancer Stem Cells Is  Critical Process which Can Be Targeted by the Antipsychotic Drug Thioridazine. 61
33297525 2020
40
circPVT1 promotes osteosarcoma glycolysis and metastasis by sponging miR-423-5p to activate Wnt5a/Ror2 signaling. 61
33369809 2020
41
Osteosarcoma: A comprehensive review of management and treatment strategies. 61
33130384 2020
42
A 3D-printed biomaterials-based platform to advance established therapy avenues against primary bone cancers. 61
33039595 2020
43
Profiling of Autophagy-Associated microRNAs in the Osteosarcoma Cell Line of U2OS. 61
33267766 2020
44
Thiostrepton and miR-216b synergistically promote osteosarcoma cell cytotoxicity and apoptosis by targeting FoxM1. 61
33193851 2020
45
Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy. 61
32060984 2020
46
In silico and in vitro analysis of FAK/MMP signaling axis inhibition by VO-clioquinol in 2D and 3D human osteosarcoma cancer cells. 61
33107537 2020
47
Chromosomal localization of Ewing sarcoma EWSR1/FLI1 protein promotes the induction of aneuploidy. 61
33293370 2020
48
Microglial annexin A3 downregulation alleviates bone cancer-induced pain through inhibiting the Hif-1α/vascular endothelial growth factor signaling pathway. 61
32569086 2020
49
Wnt5b/Ryk-mediated membrane trafficking of P2X3 receptors contributes to bone cancer pain. 61
32979370 2020
50
Temporal bone resection for lateral skull-base malignancies. 61
32108295 2020

Variations for Bone Cancer

Copy number variations for Bone Cancer from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 70082 12 58138784 58142025 Amplification TSPAN31 Bone cancer
2 70083 12 58141509 58146230 Amplification CDK4 Bone cancer
3 71134 12 67700000 68661632 Amplification MDM2 Bone cancer

Expression for Bone Cancer

Search GEO for disease gene expression data for Bone Cancer.

Pathways for Bone Cancer

Pathways related to Bone Cancer according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.61 TP53 PENK MMP9 MAPK7 IL6 ESR1
2
Show member pathways
13.44 TP53 TNFSF11 PENK MAPK7 IL6 ESR1
3
Show member pathways
13.24 TNFSF11 PENK MAPK7 IL6 EGFR CCL2
4
Show member pathways
13.1 TP53 MAPK7 IL6 CYCS CDKN2A BMI1
5
Show member pathways
13.03 TP53 PENK IL6 EGFR COL1A1 BMP2
6
Show member pathways
13.01 TP53 MMP9 IL6 EGFR CYCS CCL2
7
Show member pathways
13 PENK MAPK7 IL6 EGFR CCL2 BMP2
8
Show member pathways
12.85 TP53 TNFSF11 MMP9 MAPK7 IL6 EGFR
9
Show member pathways
12.83 TP53 IL6 EGFR CYCS CDKN2A CCL2
10
Show member pathways
12.73 TP53 TNFSF11 ESR1 EGFR CDKN2A
11
Show member pathways
12.61 TP53 MMP9 ESR1 EGFR CDKN2A
12
Show member pathways
12.6 PDYN MAPK7 EGFR CYCS BMP2
13 12.58 TP53 MMP9 IL6 ESR1 EGFR CYCS
14
Show member pathways
12.37 PENK MAPK7 IL6 EGFR BMP2
15 12.37 TP53 MMP9 MAPK7 EGFR CDKN2A BMI1
16
Show member pathways
12.3 MMP9 MAPK7 IL6 CCL2
17
Show member pathways
12.27 TP53 IL6 EGFR BMP2
18
Show member pathways
12.22 TP53 EGFR COL1A1 CCL2
19 12.2 TP53 MMP9 IL6 BMI1
20 12.19 TP53 MMP9 ESR1 EGFR COL1A1
21
Show member pathways
12.16 TP53 PENK IL6 EGFR BMP2
22 12.09 TP53 MMP9 IL6 EGFR
23 11.98 TP53 MMP9 MAPK7 CCL2
24 11.85 TP53 MMP9 IL6 CCL2
25 11.76 TP53 MMP9 BMI1
26 11.71 TP53 CYCS CDKN2A
27 11.65 MMP9 EGFR CYCS
28 11.63 MMP9 IL6 EGFR
29 11.62 TP53 CDKN2A BMP2 ATF3
30 11.62 TP53 MMP9 EGFR CDKN2A
31 11.61 MMP9 IL6 CCL2
32 11.61 PENK MAPK7 IL6 EGFR BMP2
33 11.58 MMP9 EGFR COL1A1
34 11.51 TP53 PDYN MMP9 IL6 EGFR CCL2
35 11.4 TNFSF11 IL6 COL1A1
36 11.38 TP53 IL6 EGFR CDKN2A
37 11.22 MMP9 IL6 CCL2
38 11.13 TP53 IL6 COL1A1 CDKN2A BMP2 BMI1
39 10.88 TNFSF11 PENK IL6 EGFR COL1A1 CCL2

GO Terms for Bone Cancer

Biological processes related to Bone Cancer according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 10.07 TRPV1 TP53 ESR1 BMP2 BMI1 ATF3
2 positive regulation of transcription, DNA-templated GO:0045893 9.98 TP53 IL6 ESR1 EGFR COL1A1 CDKN2A
3 positive regulation of cell migration GO:0030335 9.9 MMP9 EGFR COL1A1 BMP2
4 cytokine-mediated signaling pathway GO:0019221 9.89 TP53 TNFSF11 MMP9 IL6 CCL2
5 positive regulation of apoptotic process GO:0043065 9.88 TRPV1 TP53 MMP9 IL6 CDKN2A BMP2
6 response to estradiol GO:0032355 9.78 PENK ESR1 EGFR COL1A1
7 osteoblast differentiation GO:0001649 9.76 PENK MRC2 COL1A1 BMP2
8 cellular response to transforming growth factor beta stimulus GO:0071560 9.71 PENK MAPK7 COL1A1
9 positive regulation of epithelial to mesenchymal transition GO:0010718 9.7 IL6 COL1A1 BMP2
10 positive regulation of gene expression GO:0010628 9.7 TP53 TNFSF11 P2RX7 IL6 CDKN2A BMP2
11 monocyte chemotaxis GO:0002548 9.69 TNFSF11 IL6 CCL2
12 cellular response to growth factor stimulus GO:0071363 9.67 TRPV1 MAPK7 EGFR BMP2
13 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 9.61 TP53 ATF3
14 positive regulation of transcription by RNA polymerase II GO:0045944 9.61 TP53 TNFSF11 MAPK7 IL6 ESR1 EGFR
15 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.58 TP53 ESR1
16 regulation of neuroinflammatory response GO:0150077 9.58 MMP9 IL6
17 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.57 TP53 ESR1
18 tooth eruption GO:0044691 9.56 TNFSF11 COL1A1
19 sensory perception of pain GO:0019233 9.56 TRPV1 PENK P2RX7 CCL2
20 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.55 TP53 MAPK7
21 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.5 TP53 IL6 EGFR
22 ossification GO:0001503 9.02 TNFSF11 MMP9 EGFR COL1A1 BMP2

Molecular functions related to Bone Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.67 TNFSF11 IL6 CCL2 BMP2
2 MDM2/MDM4 family protein binding GO:0097371 9.32 TP53 CDKN2A
3 identical protein binding GO:0042802 9.28 TRPV1 TP53 TNFSF11 P2RX7 MMP9 ESR1
4 nitric-oxide synthase regulator activity GO:0030235 9.26 ESR1 EGFR
5 opioid receptor binding GO:0031628 9.16 PENK PDYN
6 opioid peptide activity GO:0001515 8.96 PENK PDYN

Sources for Bone Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....